Jefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...

Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.

Good day, ladies and gentlemen, and welcome to the Dynavax Technologies' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded. At the end of the company's ...

Detailed price information for Dynavax Technologies (DVAX-Q) from The Globe and Mail including charting and trades.

Two of GSK Plc’s blockbuster vaccines delivered lower than expected sales in the third quarter after the British drugmaker ...

Quarterly sales of GSK's RSV vaccine dropped more than 70%, following narrower recommendations for who should get the shot.

Based on the shingles incidence rate from the placebo arm North American cohort of ZOSTER-006, a Phase 3 trial of Shingrix, 10 of the 876 participants in the Phase 2 trial should have been diagnosed ...

General Medicines Growth: 7% for the quarter. Vaccines Sales Decline: 15% for the quarter due to lower sales of Arexvy and Shingrix. Core Operating Profit Growth: 5% excluding COVID. Core EPS ...

The gilts market has much to think about following Labour’s first Budget for 14 years. Gordon Brown may have tested everyone’s patience with his raid on pension funds in 1997 and higher taxes ...

The British pharma’s experience during the third quarter mirrored that of rival Pfizer, which also reported lower sales of ...

Shares of GSK plc were losing more than 4 percent on the London Stock Exchange as well as in the early morning trading on the NYSE ...